- Home
- ICE vs KZR Comparison
ICE vs KZR Comparison
Compare ICE & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICE | KZR |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.2B | 45.8M |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ICE | KZR |
|---|---|---|
| Price | $164.18 | $6.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 4 |
| Target Price | ★ $194.30 | $6.00 |
| AVG Volume (30 Days) | ★ 3.2M | 30.4K |
| Earning Date | 02-05-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ 30.10 | N/A |
| EPS | ★ 5.49 | N/A |
| Revenue | ★ $9,750,000,000.00 | N/A |
| Revenue This Year | $7.78 | N/A |
| Revenue Next Year | $5.73 | N/A |
| P/E Ratio | $29.79 | ★ N/A |
| Revenue Growth | ★ 6.48 | N/A |
| 52 Week Low | $142.29 | $3.53 |
| 52 Week High | $189.35 | $6.95 |
Technical Indicators
Market Signals| Indicator | ICE | KZR |
|---|---|---|
| Relative Strength Index (RSI) | 65.21 | 59.91 |
| Support Level | $159.66 | $6.22 |
| Resistance Level | $162.29 | $6.37 |
| Average True Range (ATR) | 2.07 | 0.10 |
| MACD | 0.26 | -0.02 |
| Stochastic Oscillator | 97.15 | 72.73 |
Price Performance
Historical ComparisonAbout ICE Intercontinental Exchange Inc.
Intercontinental Exchange is a vertically integrated operator of financial exchanges and provides ancillary data products. Though the company is probably best known for its ownership of the New York Stock Exchange, which it acquired in 2013, ICE operates a large derivatives exchange, too. The company's largest commodity futures product is the ICE Brent crude futures contract. In addition to the exchanges business, which is about 54% of net revenue, Intercontinental Exchange has used a series of acquisitions to create its mortgage technology business (22% of net revenue) and fixed-income and data services segment (24% of net revenue).
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.